Member Contact: Tim Oldham
Position: CEO and Managing Director
Industry: Biotech & Pharmaceuticals
AdAlta Limited is a Melbourne, Australia-based clinical stage drug development company. The company is focused on using its proprietary i-body technology platform to generate a new class of protein therapeutics with the affinity and specificity of monoclonal antibodies and the beneficial stability features of small molecules. AdAlta is utilising the power of its i-body technology platform to develop an internal pipeline of i-bodies enabled drugs and is also actively establishing co-development partnerships with other biopharmaceutical companies. AdAlta is initially focused on treating fibrotic disease and is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. Phase I clinical trials commenced in mid-2020.